2016 West Lake International Medical Forum Held in Hangzhou Under the Theme 'Returning Technology to Healthcare'

On October 14, the 2016 “West Lake Health” International Summit was grandly held at the Hangzhou International Conference Center. The event was hosted by the Organizing Committee of the Hangzhou West Lake International Expo and the Administrative Committee of Hangzhou Economic and Technological Development Zone, organized by Hangzhou Jianpei Technology Co., Ltd., and co-organized by the Zhejiang Health Information Society, Alibaba Cloud, the Chinese American Clinical Oncology Society (CACO), the Baihua Association, the Precision Health Management Branch of the China Pharmaceutical News and Information Association, Hangzhou Dianzi University, Firestone Creation, and VCBeat.

As one of the opening forums and the main forum for the medical sector of the 18th China Hangzhou West Lake International Expo, the event brought together more than 800 attendees, including academicians, scholars, and experts from the medical fields in the United States, Japan, India, and China, as well as IT specialists, healthcare entrepreneurs, media representatives, and government officials, to jointly explore the theme “Letting Technology Return to Healthcare Itself.” 

During the event, Li Lanjuan, Academician of the Chinese Academy of Engineering and former Director of the Zhejiang Provincial Health Department; He Lin, Academician of the Chinese Academy of Sciences, Academician of The World Academy of Sciences, and Chang Jiang Scholar Distinguished Professor; Mr. Hiroshi Fujita, Chairman of the Japanese Society for Medical Imaging and Information Sciences; Mr. David Flores, Chairman of BioCentury; Ms. Li Hong, Chief Architect of Alibaba Cloud Healthcare; and Mr. Cheng Guohua, CEO of GenPro Technology, participated in a roundtable discussion themed “Returning Technology to the Essence of Healthcare.”

In addition, the forum achieved two domestic firsts: one was the “Man vs. Machine Challenge,” where senior imaging diagnosis experts competed head-to-head with AI-powered image-reading robots on site, showcasing the cutting-edge artificial intelligence technologies driven by big data; the other was a live China-U.S. connected multidisciplinary team (MDT) consultation, bringing together world-class cancer treatment experts to demonstrate the latest advancements in the treatment of various cancers.

As the main forum of the medical sector at the Hangzhou West Expo International Fair, the 2016 "West Lake Health Talk" International Summit aimed to "promote the development of medical technology through the deep integration of academia, healthcare, technology, and capital." The summit focused on discussing how IT technology can provide more effective technological support for challenges encountered in cancer treatment, AI-driven healthcare, big data healthcare, and healthcare information systems. This event marked another major international gathering in the field of healthcare hosted by Hangzhou following the G20 Summit.

Academician Li Lanjuan:Academician of the Chinese Academy of Engineering, Leader of the National Key Discipline in Infectious Diseases and Director of the Key Laboratory of Infectious Diseases under the Ministry of Health,China's Pioneer of Artificial Liver, originalDirector of the Zhejiang Provincial Health Department, Director of the Key Laboratory of Infectious Diseases under the Ministry of Health, Professor, Chief Physician, and Doctoral Supervisor; Standing Council Member of the Chinese Women Doctors Association; Council Member of the Chinese Medical Association; President of the Zhejiang Branch of the Chinese Medical Association; Vice President of the Chinese Medical Association; Deputy Chairman of the Infectious Diseases Society of the Chinese Medical Association; Deputy Chairman of the Microecology Society of the Chinese Preventive Medicine Association; Head of the Liver Failure and Artificial Liver Group; and Director of the National Artificial Liver Training Base.

Academician Jin Li:Academician of the Chinese Academy of Sciences, Vice President of Fudan University. Cheung Kong Scholar of the Ministry of Education, Chief Scientist of the National 973 Program, recipient of the National Science Fund for Distinguished Young Scholars in 2006, and selected for the National “Thousand Talents Program” in 2011. Principal Investigator at the State Key Laboratory of Genetic Engineering, External Member of the Max Planck Society (Germany), evolutionary geneticist, and a leading figure in human genomics research. His long-term research focuses on the genetic diversity of human populations and the evolutionary mechanisms underlying human traits. He has proposed multiple theories and methods in the field of genetic diversity analysis; comprehensively characterized the genetic diversity of East Asian populations at the genomic level; elucidated the molecular genetic basis of adaptive variations for multiple traits in East Asian populations; and revealed that genetic susceptibility to diseases is closely associated with natural selection. 

Academician He Lin:Academician of the Chinese Academy of Sciences, Academician of The World Academy of Sciences (TWAS), Chang Jiang Scholar Distinguished Professor, National Distinguished Young Scholar, and genetic biologist. Chair Professor at Shanghai Jiao Tong University; Director of the Bio-X Institutes; Deputy Director of the Academic Committee of Shanghai Jiao Tong University; Professor at the Institutes of Biomedical Sciences, Fudan University; and Researcher at the Institute of Nutrition and Health, Chinese Academy of Sciences. He served twice as Chief Scientist for the National 973 Program, was an expert for the National 863 Program, a reviewer for the National Natural Science Foundation of China, and a member of the Academic Degrees Committee of the State Council. His primary research interests include disease and health (with a focus on monogenic disorders and polygenic diseases, particularly psychiatric disorders), nutrition and health, translational medicine, pharmacogenomics, and DNA computing and technology.

Academician Wang Hongyang:Academician of the Chinese Academy of Engineering and Academician of The World Academy of Sciences (TWAS, formerly known as the Third World Academy of Sciences); Distinguished Professor under the Ministry of Education’s Chang Jiang Scholars Program; recipient of the State Council Special Government Allowance. He currently serves as Director of the National Center for Liver Cancer Science and Director of the International Cooperation Research Center for Biological Signal Transduction. He also holds the position of Director of the Medical Sciences Department at the National Natural Science Foundation of China. Additionally, he is a member of the National Committee of the Chinese People’s Political Consultative Conference, Director of the Signal Transduction Research Center at the Eastern Hepatobiliary Surgery Hospital of the Second Military Medical University, and Director of the State Key Laboratory of Oncogenes and Related Genes at Shanghai Jiao Tong University School of Medicine. In February 2016, he was awarded the second Shulan Medical Award. He has long been engaged in basic and clinical research on tumors, making significant contributions to tumor signal transduction. He isolated and identified MXR7/GPC3, a gene highly expressed in liver cancer tissues, from hepatocellular carcinoma samples. MXR7 is globally recognized by the medical community as the serological screening marker with the greatest application potential for early diagnosis of liver cancer, improving the accuracy of early liver cancer diagnosis by 15% compared to previous methods.

Professor Guo Qing:Vice President of Zhejiang Chinese Medical University; Senior Research Scholar at Harvard University, USA; President of the Precision Health Management Branch of the China Pharmaceutical News and Information Association; Recipient of the State Council Special Government Allowance; Vice Chairperson of the Health Management Branch of the Chinese Medical Association; Vice Chairman of the China Health Management Industry-Academia-Research Alliance; Named one of the Top Ten Figures in China’s Healthcare Reform News; National Outstanding Scientific and Technological Worker; Recipient of the Advanced Individual Award for Industry-Academia-Research Cooperation and Innovation; Recipient of the First China Health Management Outstanding Contribution Award; Chairperson of the Health Care Branch of the Chinese Preventive Medicine Association. Main research interests: primary health care and community health services, health policy and management.

Paul A. Bunn, M.D.:Chair of Lung Cancer Research at the University of Colorado, and a world-renowned authority in the field of lung cancer treatment. Recipient of the David A. Karnofsky Memorial Award, the highest academic honor at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO). Former President of the American Society of Clinical Oncology. Dr. Bunn has guided numerous national and local clinical trials for lung cancer, and his research achievements are celebrated worldwide and have become the standard for lung cancer treatment. He has published over 300 articles on lung cancer in peer-reviewed journals, along with 122 commentaries and 90 book chapters. Dr. Bunn serves as the principal investigator for many national and local clinical trials and is the lead researcher for Grant (Spore) in translational lung cancer research.

Hiroshi Fujita, Hiroshi Fujita:Director of the Department of Intelligent Image Information, Gifu University Graduate School of Medicine; President of the Japanese Society for Medical Imaging and Information Sciences. His research encompasses the development of Computer-Aided Diagnosis (CAD) systems, image analysis and processing, and medical image evaluation. Dr. Fujita has published more than 500 papers. He is dedicated to the research and development of CAD systems for X-ray imaging. The purpose of CAD is to provide objective information derived from computer-based image data analysis as a reference (second opinion) for physicians’ diagnoses. In addition to alleviating the heavy workload associated with reading large volumes of images, CAD helps reduce misinterpretations arising from subjective judgment, thereby preventing misdiagnosis.

Professor Liu Jie:Changjiang Scholar Distinguished Professor; Recipient of the National Science Fund for Distinguished Young Scholars; Director of the Institute of Digestive Diseases, Fudan University. Primarily engaged in research on complex clinical cases and the comprehensive diagnosis and treatment of digestive tumors, including early warning systems for tumors, screening and intervention for high-risk patients, and the selection of individualized, precise, comprehensive treatment and rehabilitation plans for cancer patients. Pioneered the establishment of a nucleic acid aptamer screening platform and identified specific nucleic acid aptaments against gastric cancer, liver cancer, and hepatitis B virus, filling a domestic gap in this field and providing novel strategies for early tumor diagnosis and the development of new anti-hepatitis B drugs.

Li Hong:Chief Architect of Alibaba Cloud Healthcare, specializing in the security of internet-based healthcare applications, imaging cloud, medical big data analytics, and regional health. With extensive experience in cloud architecture for healthcare applications, he has supported projects such as the cloud applications at Shanghai Huashan Hospital and the Guangdong Provincial Cloud Hospital. He is dedicated to exploring the integration of cloud computing, big data, and healthcare services.

Dr. Li Tiantian:Founder and Chairman of DXY. The platform he founded, DXY, is China’s largest professional community for physicians. He holds a Master’s degree in Tumor Immunology and a Ph.D. in Bioinformatics, both from Harbin Medical University. He currently serves as a Visiting Professor at the Second Military Medical University.

Sanjiv Agarwala：Director of Clinical Oncology and Hematology at the St. Luke’s Cancer Research Center, Dr. Sanjiv is an internationally recognized authority in immunotherapy and a leading figure in the field of oncology and hematology. He has earned global acclaim for his research and treatment of melanoma and skin cancer. Dr. Sanjiv is dedicated to the study of targeted therapies for melanoma and is widely recognized internationally for his contributions to the fields of melanoma and immunology. He also serves as a member of the Melanoma Core Committee of the Eastern Cooperative Oncology Group (ECOG).

Professor Li Lihua:Recipient of the National Science Fund for Distinguished Young Scholars, and a national-level candidate selected under the "New Century Hundred, Thousand, and Ten Thousand Talents Project." He is a Professor at the School of Life Information and Instrument Engineering, Hangzhou Dianzi University. Prior to returning to China, he served as an Associate Professor at the University of South Florida and as a Researcher at the H. Lee Moffitt Cancer Center & Research Institute in the United States. His primary research focuses on information processing theories and technologies in life sciences, conducting theoretical research and technological innovations centered on biomedical informatics and healthcare informatization in the context of early tumor diagnosis and personalized treatment. He is dedicated to developing effective biomedical informatics theories, methods, and technologies to assist physicians in better diagnosing, treating, and managing diseases.

David Flores：Chairman and Partner of BioCentury. He graduated from the University of California, Berkeley, and holds an MBA degree from Stanford University. With over 25 years of experience in researching and developing information products in the field of biotechnology, he is a recognized authority in this domain. He also holds key positions on the Advisory Board of Northwestern University’s Office of Innovation, the Keck Advisory Board of the Graduate School of Applied Life Sciences, and the Institute for Business Management at Stanford University’s Graduate School of Business.

Chen Xinshi:Professor, currently serving as Deputy Editor-in-Chief of the Editorial Board of the Chinese Medical Journal under the Chinese Medical Association, President of the Branch Office of the Chinese Medical Association Publishing House, and Director of the Editorial Department of the Chinese Medical Journal. Concurrently holds the positions of Committee Member of the Medical Editing Committee of the China Society of Scientific and Technical Journal Editors, and Vice Chairperson of the Evidence-Based Medicine Branch of the China International Exchange and Promotive Association for Medical and Health Care.

Dr. Shen Jianying:Core member of Tu Youyou’s team. Primarily engaged in basic medical research, with expertise in the pharmacology of traditional Chinese medicine (TCM), infection immunology, and the activation and signal transduction of tyrosine kinase receptors. Has published 12 papers in journals such as PANS. Main research interests: TCM pharmacology; R&D of new TCM drugs (development of artemisinin-based compounds as anticancer agents).

David Garfield, David Garfield:A board-certified medical oncologist by the American Society of Clinical Oncology, with extensive experience in comprehensive hematologic oncology, lung cancer, breast cancer, abdominal malignancies, and general clinical oncology research. With over 40 years of professional experience in hematology and oncology, Professor Garfield has conducted particularly in-depth research on lung cancer. He served as a founding member and Chairman of the American Lung Cancer Board and held the position of Associate Professor of Clinical Medicine at the University of Colorado. Professor Garfield has authored numerous books and frequently publishes in top-tier international medical journals. He currently serves as Deputy Chief Medical Officer at Shanghai Berry Oncology. 

Dr. Wang Yueying:Recipient of the National Natural Science Foundation for Excellent Young Scholars, currently affiliated with the Shanghai Institute of Hematology at Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. Serves as a Doctoral Supervisor and Principal Investigator (PI), dedicated to scientific exploration of the pathogenesis and targeted therapy of leukemia, as well as clinical translational research. Holds positions as a Council Member of the 4th Youth Federation of Ruijin Hospital, a Member of the Chinese Society of Pathophysiology, and a Member of the European Hematology Association.